CD20 is highly significant in clinical settings, particularly in the diagnosis and treatment of B-cell malignancies. It is expressed in the majority of B-cell non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL). Targeting CD20 with monoclonal antibodies, such as Rituximab, has become a standard treatment for these conditions. Rituximab binds to CD20, initiating cell death through various mechanisms, including complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).
